Journey Medical Corporation (DERM)

NASDAQ: DERM · IEX Real-Time Price · USD
4.130
+0.180 (4.56%)
At close: Mar 1, 2024, 4:00 PM
4.000
-0.130 (-3.15%)
After-hours: Mar 1, 2024, 6:04 PM EST
4.56%
Market Cap 76.44M
Revenue (ttm) 79.89M
Net Income (ttm) -12.35M
Shares Out 18.51M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,410
Open 3.950
Previous Close 3.950
Day's Range 3.860 - 4.135
52-Week Range 1.020 - 8.110
Beta 0.97
Analysts Strong Buy
Price Target 7.25 (+75.55%)
Earnings Date Mar 27, 2024

About DERM

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for... [Read more]

Sector Healthcare
IPO Date Nov 12, 2021
Employees 20
Stock Exchange NASDAQ
Ticker Symbol DERM
Full Company Profile

Financial Performance

In 2022, DERM's revenue was $73.67 million, an increase of 16.69% compared to the previous year's $63.13 million. Losses were -$29.63 million, -32.65% less than in 2021.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 75.55% from the latest price.

Price Target
$7.25
(75.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea

Other symbols: FBIO
2 months ago - GlobeNewsWire

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to s...

Other symbols: FBIO
2 months ago - GlobeNewsWire

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023

Other symbols: FBIO
3 months ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023

Other symbols: FBIO
4 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide...

Other symbols: FBIO
4 months ago - GlobeNewsWire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission ...

Other symbols: FBIO
4 months ago - GlobeNewsWire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...

Other symbols: FBIO
6 months ago - GlobeNewsWire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023

Other symbols: FBIO
7 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET

Other symbols: FBIO
7 months ago - GlobeNewsWire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corpor...

Other symbols: FBIO
8 months ago - GlobeNewsWire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues

Other symbols: FBIO
8 months ago - GlobeNewsWire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and...

Other symbols: FBIO
8 months ago - GlobeNewsWire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues

Other symbols: FBIO
9 months ago - GlobeNewsWire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold co...

Other symbols: FBIO
10 months ago - GlobeNewsWire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...

Other symbols: FBIO
10 months ago - GlobeNewsWire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

Company to host conference call to discuss financial results and provide a corporate update on May 11, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...

Other symbols: FBIO
10 months ago - GlobeNewsWire

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Generated record total revenues of $73.7 million for the full year 2022

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and c...

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the d...

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

Phase 3, registrational studies remain on track for first half of 2023 topline data readout Phase 3, registrational studies remain on track for first half of 2023 topline data readout

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

SCOTTSDALE, Ariz., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the developm...

Other symbols: FBIO
1 year ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million

Other symbols: FBIO
1 year ago - GlobeNewsWire